# p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

> **NCT02098343** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 247 (actual)

## Conditions studied

- Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

## Interventions

- **DRUG:** APR-246
- **DRUG:** Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

## Key facts

- **NCT ID:** NCT02098343
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098343, "p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02098343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*